Advertisement
News
Advertisement

EnVivo begins Phase 1 Alzheimer's drug trial

Mon, 06/27/2011 - 10:36am
Mass High Tech: The Journal of New England Technology

EnVivo Pharmaceuticals Inc. of Watertown, which focuses on central nervous system therapies, said it has started a Phase 1 trial of its EVP-0962 Alzheimer’s drug candidate in healthy volunteers.

The drug is a selective gamma secretase modulator that is being tested for safety, tolerability, pharmacokinetics, pharmacodynamics and food effects. The company said it has shown promising results in preclinical cellular and transgenic models, where genetic material has been transferred from one organism to another, of Alzheimer’s.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading